Chronic Myeloid Leukemia: From Targeted Therapy to Treatment-Free Remission

6,105
Total downloads
24k
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 14 May 2025

Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study

Ziyu Wen
Zhi Liu
Xu Ye
Zhiping Fan
Ren Lin
Fen Huang
Li Xuan
Xiaofang Li
Hua Jin
7 more
Na Xu

doi 10.3389/fimmu.2025.1546371

2,059 views

ORIGINAL RESEARCH

Published on 19 Jul 2023

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

Alberto Blanco Sánchez
Rodrigo Gil Manso
Gonzalo Carreño-Tarragona
Diana Paredes Ruiz
Jesús González Olmedo
Joaquín Martínez-López
Carmen Díaz Pedroche
Rosa Ayala

doi 10.3389/fphar.2023.1206893

1,396 views
1 citation

ORIGINAL RESEARCH

Published on 04 Jul 2023

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients

Henrike Jacobi
Margherita Vieri
Marlena Bütow
Carolina Y. Namasu
Laura Flüter
Ivan G. Costa
Tiago Maié
Katharina Lindemann-Docter
Nicolas Chatain
5 more
Mirle Schemionek

doi 10.3389/fphar.2023.1212392

4,339 views
6 citations

ORIGINAL RESEARCH

Published on 31 May 2023

Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo

Bharathi M. Rajamani
Raveen Stephen Stallon Illangeswaran
Esther Sathya Bama Benjamin
Balaji Balakrishnan
Daniel Zechariah Paul Jebanesan
Saswati Das
Aswin Anand Pai
Rakhi Thalayattu Vidhyadharan
Ajith Mohan
4 more
Poonkuzhali Balasubramanian

doi 10.3389/fphar.2023.1187066

3,041 views
4 citations

ORIGINAL RESEARCH

Published on 26 May 2023

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells

Paola Pacelli
Adele Santoni
Anna Sicuranza
Elisabetta Abruzzese
Valentina Giai
Monica Crugnola
Mario Annunziata
Sara Galimberti
Alessandra Iurlo
10 more
Monica Bocchia

doi 10.3389/fphar.2023.1194712

2,490 views
11 citations

BRIEF RESEARCH REPORT

Published on 23 Mar 2023

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

A. Iurlo
D. Cattaneo
D. Consonni
F. Castagnetti
M. C. Miggiano
G. Binotto
M. Bonifacio
G. Rege-Cambrin
M. Tiribelli
25 more
M. Breccia

doi 10.3389/fphar.2023.1154377

2,269 views
13 citations

ORIGINAL RESEARCH

Published on 16 Mar 2023

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience

Tamara Chitanava
Iuliia Matvienko
Vasily Shuvaev
Sergey Voloshin
Irina Martynkevich
Yulia Vlasova
Elizaveta Efremova
Ekaterina Mileeva
Anna Pirkhalo
14 more
Elza Lomaia

doi 10.3389/fonc.2023.1138683

1,953 views

CASE REPORT

Published on 16 Mar 2023

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance

Jusuf Imeri
Christophe Desterke
Paul Marcoux
Diana Chaker
Noufissa Oudrhiri
Xavier Fund
Jamila Faivre
Annelise Bennaceur-Griscelli
Ali G. Turhan

doi 10.3389/fonc.2023.1117781

642 views
1 citation

ORIGINAL RESEARCH

Published on 23 Jan 2023

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice

Yilin Chen
Huifang Zhao
Jingming Guo
Jing Zou
Wenjuan He
Danlei Han
Fanjun Cheng
Yanli Zhang
Weiming Li

doi 10.3389/fphar.2023.1101743

2,130 views
4 citations

ORIGINAL RESEARCH

Published on 06 Dec 2022

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

Elena Karg
Christoph Baldow
Thomas Zerjatke
Richard E. Clark
Ingo Roeder
Artur C. Fassoni
Ingmar Glauche

doi 10.3389/fonc.2022.1028871

1,708 views
6 citations

Share on

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Participating Journals

Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- 3.3 impact factor
- 6.9 citescore

Impact

24kTopic views
17kArticle views
6,105Article downloads

View impact

Articles

Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients

Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Participating Journals

Frontiers in Oncology

Pharmacology of Anti-Cancer Drugs